Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (3105)	9/20/2003 3:49:59 PM
From: Jibacoa	Read Replies (1) \| Respond to of 23958

Joe: LSBC has been on a long term down-trend for quite some time.<g> Its primary down-trend started after its monthly triple top (August-September-October 2000) at the 33.50 level. siliconinvestor.com That continued, and after the November 2001-January 2002 double top at the 5 level,it seems that a bottom was found at its March-April 2003 Ls ( 0.34 to 0.40 level.<g>) On April 24 it was able to trade above the $1 level with a spurt in volume (1.773M)Although the stock wasn't able to close above $1 that day (C was 0.89) it was able to start a short term up-trend that ended on the June 6-June 9 double top at the $1.60 level, to which I made reference on my previous note.<g> Regarding your comments " I bet they have some partnerships agreement coming up" As you know,when NTB and GRA terminated their "partnerships",LSBC's downtrend accelerated,however LSBC is still using the tobacco plants.<g> On May 21,2003 LSBC announced that its biomanufacturing operation in Ky is gearing up to produce an enzyme to treat Fabry disease, growing it in tobacco plants and will demonstrate that it can produce quantities large enough for human clinical trials. The FDA designated LSBC's product as an orphan drug in January which will give LSBC 7 yrs. protection from competition, plus tax incentives to help cover research costs.(There is an estimated $1B market in the US and Europe.) LSBC is seeking a commercial partner, which could cover the cost of clinical trials. Last October they announced a worldwide licensing agreement with A. agilent.com Last month they announced an agreement with GRG of CA to develop a non-GMO product to control plant pests. They also said last month that they plan to enter the research grade aprotinin market during the second quarter of 2004. (Estimates for research grade aprotinin range up to $20M/yr.) I have a small long position on LSBC and,as I mentioned, may consider adding after it can close above $1.60 <g> siliconinvestor.com Bernard

To: JoeinIowa who wrote (3105)	9/20/2003 7:32:01 PM
From: Sergio H	Respond to of 23958

If I have to start checking Bernard's sales as well as yours I would be too busy to look after my own picks. You guys are going to have to start doing a better job of knowing when to fold. That goes for whomever sold MPET as well. I'm finding lots of charts I like but not the accompanying fundamentals that would interest me enough to buy and hold. To list a few: WEDX, INSG, AIGX, AVGN, CANI, TWAV, FLOW LSBC also has a bullish chart, an inverted head and shoulder pattern. Sergio